查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1592907

流感診斷市場：按測試類型、最終用戶分類 - 2025-2030 年全球預測

Influenza Diagnostics Market by Test Type (Cell Culture, Rapid Influenza Diagnostic Tests, Reverse Transcription-Polymerase Chain Reaction), End-User (Hospitals, Laboratories, Point-Of-Care Testing) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年流感診斷市值為12億美元，預計2024年將達13.2億美元，複合年成長率為9.86%，預計到2030年將達到23.2億美元。

流感診斷市場包括識別流感病毒感染的工具和流程。這項需求源自於流感病毒的全球大流行，流感病毒每年都會導致嚴重的發病率和死亡率。快速、準確的診斷對於病例管理、流行病學監測和疫情預防至關重要。這些診斷的應用涵蓋醫院、診所、診斷實驗室和研究機構，對於指南臨床決策、管理公共衛生反應和開發疫苗至關重要。此外，一些流感病毒株感染疾病的，因此最終用途包括人類保健和獸醫應用。

主要市場統計
基準年[2023] 12億美元
預測年份 [2024] 13.2億美元
預測年份 [2030] 23.2億美元
複合年成長率（%） 9.86%

流感診斷市場的主要成長要素包括技術進步、對就地檢驗需求的增加以及由於最近的流行病而引起的對感染疾病的日益關注。人口老化和慢性呼吸道疾病盛行率上升將進一步推動需求，推動市場強勁成長。市場開拓機會包括開發可以同時檢測多種病原體、提高效率和患者治療效果的多重診斷平台。公司可以利用向新興市場擴張的機會，這些市場的醫療保健基礎設施的改善正在增加獲得診斷的機會。

然而，市場成長面臨的挑戰包括先進診斷的高價格、某些地區的保險報銷有限以及需要熟練的專業人員操作複雜的診斷設備。此外，流感病毒的快速突變使有效診斷的開發變得複雜。創新機會在於開發更快、更具成本效益和更易於使用的診斷解決方案，例如使用 CRISPR 技術和紙基生物感測器的解決方案。此外，整合人工智慧來提高診斷準確性和預測流感爆發為研究和業務成長提供了一個有前景的領域。市場的特點是技術快速發展、競爭激烈，需要持續創新和策略聯盟來保持競爭力。

市場動態：快速發展的流感診斷市場的關鍵市場洞察

供需的動態交互作用正在改變流感診斷市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 流感流行和流感篩檢檢測增加
    • 增加流感診斷研究經費
    • 提高使用特定診斷測試進行早期檢測和診斷的意識
  • 市場限制因素
    • 核准新診斷測試的嚴格法律規範
  • 市場機會
    • 開發先進的診斷測試，例如 CLIA 豁免的 POC 分子流感測試
    • 擁有強大的經銷網路
  • 市場挑戰
    • 醫療費用上漲

波特五力：駕馭流感診斷市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解流感診斷市場的外部影響

外部宏觀環境因素在塑造流感診斷市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解流感診斷市場的競爭狀況

對流感診斷市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

流感診斷市場中的 FPNV 定位矩陣供應商績效評估

FPNV定位矩陣是評估流感診斷市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪流感診斷市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對流感診斷市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 流感流行和流感篩檢檢測增加
      • 增加流感診斷研究經費
      • 透過特定的診斷測試提高早期檢測和快速診斷的意識
    • 抑制因素
      • 核准新診斷測試的嚴格法規結構
    • 機會
      • 開發先進的診斷測試，例如 CLIA 豁免的 POC 分子流感測試
      • 強大的分銷網路的可用性
    • 任務
      • 醫療費用上漲
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章按測試類型分類的流感診斷市場

  • 細胞培養
  • 流感快速診斷檢測
  • 逆轉錄聚合酵素鏈鎖反應

第7章流感診斷市場：依最終使用者分類

  • 醫院
  • 研究所
  • 就地檢驗

第8章美洲流感診斷市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區流感診斷市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲的流感診斷市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Aetna Inc.
  • Becton, Dickinson and Company
  • Cepheid
  • Co-Diagnostics, Inc.
  • DIASORIN MOLECULAR LLC
  • F. Hoffmann-La Roche Ltd.
  • Luminex Corporation
  • Merck KGaA
  • Quidel Corporation
  • SA Scientific Ltd.
  • Sansure Biotech Inc.
  • Secure Diagnostics Pvt. Ltd.
  • Sekisui Diagnostics, LLC
  • Thermo Fisher Scientific Inc.
Product Code: MRR-43127F72796F

The Influenza Diagnostics Market was valued at USD 1.20 billion in 2023, expected to reach USD 1.32 billion in 2024, and is projected to grow at a CAGR of 9.86%, to USD 2.32 billion by 2030.

The influenza diagnostics market involves tools and processes used to identify influenza virus infections. Its necessity stems from the global prevalence of the influenza virus, which causes significant morbidity and mortality annually. Rapid and accurate diagnostics are crucial for patient management, epidemiological surveillance, and the prevention of outbreaks. The application of these diagnostics spans hospitals, clinics, diagnostic laboratories, and research institutions, where they are essential for guiding clinical decisions, managing public health responses, and developing vaccines. Additionally, their end-use includes both human healthcare and veterinary applications, given the zoonotic nature of some influenza strains.

KEY MARKET STATISTICS
Base Year [2023] USD 1.20 billion
Estimated Year [2024] USD 1.32 billion
Forecast Year [2030] USD 2.32 billion
CAGR (%) 9.86%

Key growth factors in the influenza diagnostics market include technological advancements, increased demand for point-of-care testing, and a heightened focus on infectious diseases due to recent pandemics. The aging population and the rising incidence of chronic respiratory diseases further drive demand, positioning the market for robust growth. Opportunities in the market include the development of multiplex diagnostic platforms that can simultaneously test for multiple pathogens, enhancing efficiency and patient outcomes. Companies can capitalize on expanding into emerging markets where healthcare infrastructure improvements are increasing access to diagnostics.

However, market growth may be challenged by the high cost of advanced diagnostics, limited reimbursement in certain regions, and the need for skilled professionals to operate complex diagnostic equipment. Additionally, the rapid mutation of influenza viruses can complicate the development of effective diagnostics. Innovation opportunities lie in the development of faster, more cost-effective, and user-friendly diagnostic solutions, such as those using CRISPR technology or paper-based biosensors. Moreover, integrating artificial intelligence to improve diagnostic accuracy and predict influenza outbreaks offers a promising area for research and business growth. The market is characterized by rapid technological evolution and competitive intensity, necessitating continuous innovation and strategic partnerships to maintain a competitive edge.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Influenza Diagnostics Market

The Influenza Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of influenza and increasing number of influenza screening test
    • Growth in research funding for influenza diagnostics
    • Growing awareness for early detection faster diagnosis using specific diagnostic tests
  • Market Restraints
    • Stringent regulatory framework for the approval of new diagnostic tests
  • Market Opportunities
    • Development of advanced diagnosis test such as CLIA-waived POC molecular influenza tests
    • Availability of strong distribution network
  • Market Challenges
    • Rising healthcare costs

Porter's Five Forces: A Strategic Tool for Navigating the Influenza Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Influenza Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Influenza Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Influenza Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Influenza Diagnostics Market

A detailed market share analysis in the Influenza Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Influenza Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Influenza Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Influenza Diagnostics Market

A strategic analysis of the Influenza Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Influenza Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aetna Inc., Becton, Dickinson and Company, Cepheid, Co-Diagnostics, Inc., DIASORIN MOLECULAR LLC, F. Hoffmann-La Roche Ltd., Luminex Corporation, Merck KGaA, Quidel Corporation, SA Scientific Ltd., Sansure Biotech Inc., Secure Diagnostics Pvt. Ltd., Sekisui Diagnostics, LLC, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Influenza Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test Type, market is studied across Cell Culture, Rapid Influenza Diagnostic Tests, and Reverse Transcription-Polymerase Chain Reaction.
  • Based on End-User, market is studied across Hospitals, Laboratories, and Point-Of-Care Testing.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of influenza and increasing number of influenza screening test
      • 5.1.1.2. Growth in research funding for influenza diagnostics
      • 5.1.1.3. Growing awareness for early detection faster diagnosis using specific diagnostic tests
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulatory framework for the approval of new diagnostic tests
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of advanced diagnosis test such as CLIA-waived POC molecular influenza tests
      • 5.1.3.2. Availability of strong distribution network
    • 5.1.4. Challenges
      • 5.1.4.1. Rising healthcare costs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Influenza Diagnostics Market, by Test Type

  • 6.1. Introduction
  • 6.2. Cell Culture
  • 6.3. Rapid Influenza Diagnostic Tests
  • 6.4. Reverse Transcription-Polymerase Chain Reaction

7. Influenza Diagnostics Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Laboratories
  • 7.4. Point-Of-Care Testing

8. Americas Influenza Diagnostics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Influenza Diagnostics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Influenza Diagnostics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Aetna Inc.
  • 3. Becton, Dickinson and Company
  • 4. Cepheid
  • 5. Co-Diagnostics, Inc.
  • 6. DIASORIN MOLECULAR LLC
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. Luminex Corporation
  • 9. Merck KGaA
  • 10. Quidel Corporation
  • 11. SA Scientific Ltd.
  • 12. Sansure Biotech Inc.
  • 13. Secure Diagnostics Pvt. Ltd.
  • 14. Sekisui Diagnostics, LLC
  • 15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. INFLUENZA DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. INFLUENZA DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. INFLUENZA DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. INFLUENZA DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INFLUENZA DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INFLUENZA DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID INFLUENZA DIAGNOSTIC TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM INFLUENZA DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. INFLUENZA DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. INFLUENZA DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023